Ophthalmology Innovation Source’s Post

🤝 In the world of 2024 pharma partnerships, no where is putting on a spectacle like ADCs and radioligands, Novartis' recent acquisition of Mariana Oncology the latest in a series of $billion deals in the last 12 months. ☀ But with the pressure to "make hay while the sun shines" how do ADC and RLT companies differentiate, validate or collaborate amidst a whirlwind of interest and activity? 🌟 ...enter the ADC & Radiopharmaceutical Pharma & Biotech Partnering Summit in Boston. The hyper-relevant partnership event delivering better access to disruptive science, capital and deals, for ADCs and RLTs. https://ter.li/ipq457 👥 Uniting S&E and BD&L from pharma with C-level and BD execs from Biotech, join the hottest and most targeted partnering initiative to gain visibility and traction across business-to-business buy/sell ADC opportunities, and align to translate the next generation of safe, effective and differentiated ADCs and RLTs through the clinic and to patients in need.

Who's ready to learn? Join us for Axtria Ignite 2024, our premier event for innovation and leadership in the industry. Learn from experts, network with peers, and get inspired by award winners, ... AND the best damned reception in the business! Register today and join us on June 12-13 in Princeton, NJ. #AxtriaIGNITE  #Leadership #Commercial #Pharma #Lifesciences Axtria - Ingenious Insights Michael Schneider

📣 Nordic Nexus: Perspectives from Pharma Deal-Making Execs on Collaborating with Biotech Innovators Join our panel of Biotech Leaders as they discuss: ·  How are deal-making executives perceiving Nordic innovation in comparison to the rest of the world and what makes a Nordic company more attractive to work with ·  Assessing the risk-reward dynamics, weighing the potential benefits of entering the Nordic biotech market against the inherent challenges and uncertainties ·  The degrees of deal structures and negotiation dynamics in collaborations between pharma and biotech, exploring flexible models that accommodate the unique needs and goals of both parties 🎙 Hear from: · Ajan Reginald, CEO, Roquefort Therapeutics plc · Keld Flintholm Jørgensen, SVP & CBO, Lundbeck · Jane Buus Laursen, CVP, Corporate Development, Novo Nordisk · Nuno Alves, PhD, Associate Director, Business Development, Astellas Pharma Find out more: https://lnkd.in/eCEU3-vJ #LSXNordic #Biotech

In 2023, the estimated average cost of developing a new medicine among the top 20 global biopharma companies rose by 15% from the previous year. 💊 And challenges with clinical trials are only adding to these rising prices. We take a look at how tech could disrupt costly trials — spotlighting one US company that could shake up the industry in Europe. #Ad with Debiopharm Featuring insights from Anca Copaescu, CEO at Strategikon and Vincent Lepreux, investment principal at Debiopharm Innovation Fund.

🌟 Exciting News in the Pharma World 🌟 Big moves happening as Eli Lilly swoops in to acquire Morphic for a whopping $3.2 billion! 💰 This strategic acquisition not only gives Lilly control of an oral rival to Takeda's Entyvio but also positions them as frontrunners in the race against competitors like Gilead Sciences and Ensho Therapeutics. 🏁 Morphic's star player, MORF-057, is making waves targeting α4β7 integrin in the development stages for ulcerative colitis and Crohn's disease. 🚀 While early data showed great potential, subsequent results led to some rollercoaster rides for Morphic's stock price. 🎢 Now all eyes are on the upcoming phase 2b trial data for ulcerative colitis and the Crohn's trial set to wrap up in 2026 to see the true impact of Lilly's investment. 💊 #PharmaNews #Innovation #EliLilly #MorphicAcquisition

Insightful discussion on the value of partnerships at Executive Insights 2024 Emphasizing that partnerships are critical for successful drug development, especially for small companies like BioArctic that rely on collaborations, Gunilla Osswald, BioArctic CEO, was one of the speakers at the Executive Insights 2024 conference hosted by Cytel, DNB, and Flerie. Osswald values partners who are truly interested in working together cooperatively to achieve strong relationships and added a sixth "R" to the classic 5R concept in pharma negotiations - focusing on the significance of relationships and their ability to advance innovation. The six Rs: - Right target - Right patient population - Right dose and exposure - Right study design - Right safety - Right collaborations

Collaboration: The powerful leverage in Drug Development BioArctic's post highlighting CEO Gunilla Osswald's revised perspective on AstraZeneca's 5R Framework for successful drug development is spot on. As a scientist with 12 years of experience leading Offspring Biosciences, a Tissue Analytics CRO, as well as previously working on the big pharma side overseeing outsourcing of research, I offer my take on this. Synergy through Collaboration: The Power of the 6th R Gunilla's insightful addition of a 6th "R" – Right Collaboration – to the existing 5R framework is a powerful recognition of the critical value CRO partnerships brings to drug development. Indeed, the CRO industry's tremendous expansion during the past 15 years is a direct reflection of the growing need for specialized expertise in today's complex drug development landscape. Beyond Execution: The Embedded Scientific Partner However, maximizing the value of these collaborations hinges on how they are structured and executed. This is where Gunilla Osswald's concept of "Right Collaboration" comes into play. My experience is that the ideal scenario involves the CRO functioning as a truly embedded scientific partner, actively involved in designing, executing, and evaluating studies that drives the projects forward to the next critical decision point. This collaborative approach stands in contrast to operative models for outsourcing where the CROs serve primarily as an extension of the pharma company's lab, executing tasks with limited input. BioArctic’s 6R framework, with its emphasis on Right Collaborations, paves the way for a more symbiotic relationship which leverages the strengths of both pharma and CRO for an accelerated and successful drug development progress. A Shared Journey As scientists and industry professionals, both within pharma and CROs, we share a common goal: advancing the development of safe and effective drugs that brings true value to our common client – the patients. Let's unlock the power of true collaborations, as outlined in the 6R framework, to turn this vision into reality. What do you think? Share your experiences from collaborative CRO partnerships in the comments! #Collaboration #DrugDevelopment https://lnkd.in/dfPpTRgc https://lnkd.in/dgPX22aV

🚀 Exciting News: Our Latest Whitepaper is Now Live! 🚀 I'm thrilled to share that my latest whitepaper, "Meeting the Moment: Alignment Between Company Formation and Stakeholder Demand Across Biopharma’s Innovation Ecosystem," is now available! 📄✨ This comprehensive study delves into the complex dynamics of biopharma innovation, exploring how emerging companies align with investors, partners, and acquirers to drive breakthroughs. 🔍 Key insights include: • Therapeutic focus alignment was strongest between emerging biopharma and IPOs, weaker between emerging biopharma and Pharma partnership deals, and weakest between emerging biopharma and M&A deals. • Alignment between emerging biopharma and IPOs was reduced during the period in which the IPO window was ‘closed’ (2022- 24) vs. when it was ‘open’ (2020-21). • When comparing emerging biopharma with Pharma deal-making (partnerships, M&As), strong misalignment in several focus categories revealed both ‘seller's market’ opportunities (benign hematology, cardiovascular disease, and antibodybased therapeutic) and ‘buyer's market’ opportunities (cell therapies), representing deal-making opportunities for emerging biopharma and large Pharma stakeholders, respectively. Whether you're an investor, industry leader, or just passionate about transformative healthcare innovations, this whitepaper provides valuable insights to navigate and capitalize on opportunities within the biopharma ecosystem. Dive into the data, uncover trends, and join the conversation on shaping the future of healthcare! 💡📈 #Biopharma #Innovation #Whitepaper #Healthcare #IPOs #EmergingMarkets #StakeholderAlignment

Insightful article from my colleague Joel Sandler, Ph.D. on the alignment between emerging biopharma company formation and stakeholder demand across the biopharma innovation ecosystem over the past 5 years. Some key takeaways: - Overall, there were strong alignment levels between the therapeutic focus of newly launched biopharma companies and the focus areas pursued by IPOs, pharma partnerships, and M&A deals - Alignment was strongest between emerging biopharma and IPOs, weaker with partnering deals, and weakest with M&As. This gradient suggests nuances in how different stakeholders perceive and act on opportunities - For IPOs specifically, alignment with emerging biopharma was stronger during the "open IPO window" of 2020-21 compared to the more skeptical "closed window" of 2022-24. - Analysis of outlier categories revealed both "seller's market" opportunities for emerging biopharma (benign hematology, cardiovascular, antibody therapies) and "buyer's market" opportunities for pharma (cell therapies). The findings provide strategic insights for key stakeholders - emerging biotechs should pursue areas of high pharma demand, pharma should diversify deals across both "seller's" and "buyer's" markets, and public investors must look beyond available IPO inventory. As the pace of scientific advancement continues, it will be important to monitor how these alignment trends evolve to enable more efficient capital allocation and ultimately better patient outcomes. It was a pleasure to help out with some of the analytics that went into this piece. Great work digging into this important topic!

Cutting edge thinking about the investments supporting upstream innovation in Biopharma from Joel Sandler, Ph.D. and the Healthcare Advisory team. #IpsosHealthcareAdvisory #Biopharma #Innovation #Investment #Whitepaper #Healthcare #IPOs #EmergingMarkets #StakeholderAlignment